Clinical trial
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in…
NCT00256217 · Rita Sanghvi, Mehta, Other · Completed
Key facts
| NCT number | NCT00256217 |
|---|---|
| Title | Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women |
| Official title | Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women |
| Lead sponsor | Rita Sanghvi, Mehta, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | DCIS |
| Intervention type | Drug |
| Interventions | Anastrozole |
| Enrollment | 42 |
| Start date | Sep 21, 2004 |
| Primary completion | Dec 12, 2018 |
| Completion | Dec 12, 2018 |
| First posted | Nov 21, 2005 |
| Last update posted | May 11, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: